2018
DOI: 10.7150/jca.21854
|View full text |Cite
|
Sign up to set email alerts
|

Investigating Esophageal Stent-Placement Outcomes in Patients with Inoperable Non-Cervical Esophageal Cancer

Abstract: Background: Esophageal stent insertion in patients with inoperable esophageal cancer is usually accompanied with relatively high adverse symptoms and even mortality. The current study aims at investigating the outcomes of esophageal stenting in patients with inoperable non-cervical esophageal cancer.Materials and Methods: The current descriptive-analytical research evaluates 25 patients with esophageal cancer. The stent was placed in esophagus based upon endoscopy analysis with or without fluoroscopy and then … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 20 publications
0
8
0
Order By: Relevance
“…Esophageal cancer (EC), which accounts for about 2% of human malignancies, is one of the most lethal malignancies in humans [ 1 ]. Among the subtypes of EC, esophageal adenocarcinoma mainly occurs in European and American countries, while in China, esophageal squamous cell carcinoma (ESCC) is the dominant histologic subtype [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…Esophageal cancer (EC), which accounts for about 2% of human malignancies, is one of the most lethal malignancies in humans [ 1 ]. Among the subtypes of EC, esophageal adenocarcinoma mainly occurs in European and American countries, while in China, esophageal squamous cell carcinoma (ESCC) is the dominant histologic subtype [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…3 Other tumors tend to have bone involvement include thyroid, melanoma and kidney, along with hematologic malignancies including myeloma and lymphoma that can also cause bone pain and destruction. 4,5 The average survival rate of patients with bone metastases is of several months. Patients with bone metastases from breast or prostate cancer may have a longer survival time.…”
mentioning
confidence: 99%
“…This justifies why these patients do not benefit from anti-acid therapy [ 24 ], and in our study, this is proven. Moreover, different studies on various subjects have published the regarding the above results [ 25 ] [ 26 ] [ 27 ] [ 28 ] [ 29 ].…”
Section: Discussionmentioning
confidence: 99%